Prismaflex st100 set has been temporarily approved for use in the us under emergency use authorization (b)(4) to deliver crrt to treat patients in an acute care environment during the covid-19 pandemic.
A batch review was conducted and there were no deviations found related to this reported condition during the manufacture of this lot.
The device was not received for evaluation; however, a picture of the impacted set was provided.
The visual inspection of the picture could not identify the reported leak, nevertheless, the reported condition could not be refuted.
The cause could not be determined.
Should additional relevant information become available, a supplemental report will be submitted.
|